| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
5,366,000 |
| Market
Cap: |
7.83(M) |
| Last
Volume: |
140,704 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.506 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company focused on developing cancer immunotherapeutics for a range of cancer indications. Co.'s product candidates include galinpepimut-S (GPS) and nelipepimut-S (NPS). Co.'s primary product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets the Wilms tumor 1 protein, which is present in 20 or more cancer types. NPS is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 expressing cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
9,806 |
| Total Sell Value |
$0 |
$0 |
$0 |
$25,516 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
3 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wasman Jane |
Director |
– • – |
2022-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
1,900 |
|
- |
|
| Wood Barbara A |
EVP, Gen. Counsel, Corp. Sec. |
• – – |
2022-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
13,000 |
55,028 |
|
- |
|
| Burns John Thomas |
Senior VP, Finance & CAO |
• – – |
2022-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
9,600 |
27,244 |
|
- |
|
| Varian John |
Director |
– • – |
2022-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
1,900 |
|
- |
|
| Scheinberg David A |
Director |
– • – |
2022-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
2,082 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2022-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
44,000 |
165,167 |
|
- |
|
| Van Nostrand Robert L |
Director |
– • – |
2022-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
1,900 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2021-12-02 |
4 |
S |
$6.25 |
$13,252 |
D/D |
(2,120) |
121,167 |
|
43% |
|
| Wood Barbara A |
EVP, Gen. Counsel, Corp. Sec. |
• – – |
2021-12-02 |
4 |
S |
$6.25 |
$5,298 |
D/D |
(847) |
42,028 |
|
43% |
|
| Burns John Thomas |
VP, Finance & Corp Controller |
• – – |
2021-12-02 |
4 |
S |
$6.27 |
$1,448 |
D/D |
(231) |
17,644 |
|
43% |
|
| Wood Barbara A |
EVP, Gen. Counsel, Corp. Sec. |
• – – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
7,875 |
32,875 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
19,750 |
98,287 |
|
- |
|
| Burns John Thomas |
VP, Finance & Corp Controller |
• – – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,875 |
12,875 |
|
- |
|
| Wood Barbara A |
EVP, Gen. Counsel, Corp. Sec. |
• – – |
2020-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
35,000 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2020-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
95,000 |
95,000 |
|
- |
|
| Burns John Thomas |
VP, Finance & Corp Controller |
• – – |
2020-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2018-12-31 |
4 |
S |
$1.25 |
$29,189 |
D/D |
(23,277) |
426,858 |
|
- |
|
| Eqc Private Markets Ii Sac Fund Ltd-Eqc Biotech Se |
Former Director, 10% holder |
– – • |
2018-09-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,523,986) |
0 |
|
- |
|
| Stergiou Andelos M. |
President and CEO |
• • – |
2017-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
450,135 |
450,135 |
|
- |
|
| Scheinberg David A |
Director |
– • – |
2017-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,107 |
9,107 |
|
- |
|
| Tafur Daniel |
10% Owner |
– – • |
2017-12-29 |
4 |
A |
$0.00 |
$0 |
I/I |
2,738,646 |
3,343 |
|
- |
|
| Hillsberg Sanford |
Director |
– • – |
2017-10-10 |
4 |
A |
$0.38 |
$7,979 |
D/D |
20,997 |
56,950 |
|
- |
|
| Gray Mary Ann |
Director |
– • – |
2017-10-10 |
4 |
A |
$0.38 |
$5,879 |
D/D |
15,472 |
39,167 |
|
- |
|
| Chin Richard |
Director |
– • – |
2017-10-10 |
4 |
A |
$0.38 |
$4,829 |
D/D |
12,708 |
31,339 |
|
- |
|
| Einhorn Irving M. |
Director |
– • – |
2017-10-10 |
4 |
A |
$0.38 |
$5,459 |
D/D |
14,366 |
34,690 |
|
- |
|
90 Records found
|
|
Page 2 of 4 |
|
|
0.01 (0.68%) 
